Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
History of aspirin preparations became a standard part of the "materia medica" of Western medicine beginning at least with the Greek physician Hippocrates in the fifth century BCE; he recommended chewing on willow bark to relieve pain or fever, and drinking tea made from it to relieve pain during childbirth. The Roman encyclopedist Celsus, in his "De Medicina" of ca. 30 AD, suggested willow leaf extract to treat the four signs of inflammation: redness, heat, swelling and pain. Willow treatments also appeared in Dioscorides's "De Materia Medica", and Pliny the Elder's "Natural History". By the time of Galen, willow bark was commonly used